Comparative Effectiveness of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Patients With Inoperable Esophageal Squamous Cell Carcinoma Undergoing Curative-Intent Concurrent Chemoradiotherapy
- PMID: 38154513
- DOI: 10.1016/j.jtho.2023.12.021
Comparative Effectiveness of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Patients With Inoperable Esophageal Squamous Cell Carcinoma Undergoing Curative-Intent Concurrent Chemoradiotherapy
Abstract
Introduction: This study compared outcomes in patients with inoperable esophageal squamous cell carcinoma (ESCC) undergoing curative-intent concurrent chemoradiotherapy (CCRT) with intensity-modulated radiotherapy (IMRT) versus intensity-modulated proton therapy (IMPT).
Methods: The study encompassed a retrospective cohort analysis of patients with inoperable ESCC who underwent curative-intent CCRT from January 1, 2015, to December 31, 2020, with data sourced from the Taiwan Cancer Registry Database. In this study, both IMRT and IMPT delivered a total equivalent effective dose of approximately 5040 cGy in 28 fractions, accompanied by platinum-based chemotherapy administered as per established protocols. Multivariate Cox regression analyses were performed to assess oncologic outcomes, and statistical analyses were conducted, including inverse probability of treatment-weighted and Fine and Gray method for competing risks.
Results: The observed risks of ESCC-specific and all-cause mortality were lower in patients treated with IMPT compared with those treated with IMRT, with adjusted hazard ratios (aHRs) of 0.62 (95% confidence interval [CI]: 0.58-0.70) and 0.72 (95% CI: 0.66-0.80), respectively. IMPT also reduced grade 2 radiation-induced side effects, such as pneumonitis, fatigue, and major adverse cardiovascular events, with aHRs (95% CI) of 0.76 (0.66-0.82), 0.10 (0.07-0.14), and 0.70 (0.67-0.73), respectively. However, IMPT was associated with an increased risk of grade 2 radiation dermatitis, with aHR (95% CI) of 1.48 (1.36-1.60). No substantial differences were found in the incidence of radiation esophagitis between IMPT and IMRT when adjusting for covariates.
Conclusion: IMPT seems to be associated with superiority over IMRT in managing patients with inoperable ESCC undergoing curative-intent CCRT, suggesting improved survival outcomes and reduced toxicity. These findings have significant implications for the treatment of ESCC, particularly when surgery is not an option.
Keywords: ESCC; IMPT; IMRT; Survival; Toxicities.
Copyright © 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The authors declare no conflict of interest.
Similar articles
-
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.JAMA Netw Open. 2021 Jun 1;4(6):e2113205. doi: 10.1001/jamanetworkopen.2021.13205. JAMA Netw Open. 2021. PMID: 34143193 Free PMC article.
-
Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.BMC Cancer. 2024 Jun 4;24(1):679. doi: 10.1186/s12885-024-12427-y. BMC Cancer. 2024. PMID: 38831450 Free PMC article. Clinical Trial.
-
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.JAMA Netw Open. 2022 Nov 1;5(11):e2241538. doi: 10.1001/jamanetworkopen.2022.41538. JAMA Netw Open. 2022. PMID: 36367724 Free PMC article.
-
Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.Oral Oncol. 2019 Jan;88:66-74. doi: 10.1016/j.oraloncology.2018.11.015. Epub 2018 Nov 21. Oral Oncol. 2019. PMID: 30616799 Free PMC article. Review.
-
Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis.Radiat Oncol. 2019 Oct 17;14(1):178. doi: 10.1186/s13014-019-1386-x. Radiat Oncol. 2019. PMID: 31623639 Free PMC article. Review.
Cited by
-
Impact of perioperative dexmedetomidine on recurrence and survival outcomes in oral cavity squamous cell carcinoma.BMJ Health Care Inform. 2025 Jul 7;32(1):e101344. doi: 10.1136/bmjhci-2024-101344. BMJ Health Care Inform. 2025. PMID: 40623770 Free PMC article.
-
Impact of long-term N-acetylcysteine use on cancer risk.Am J Cancer Res. 2025 Feb 15;15(2):618-630. doi: 10.62347/VCDJ1296. eCollection 2025. Am J Cancer Res. 2025. PMID: 40084379 Free PMC article.
-
Advances in the treatment of unresectable locally advanced esophageal squamous carcinoma (Review).Mol Clin Oncol. 2025 Apr 3;22(6):50. doi: 10.3892/mco.2025.2845. eCollection 2025 Jun. Mol Clin Oncol. 2025. PMID: 40242367 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical